-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CG-750 in Idiopathic Pulmonary Fibrosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CG-750 in Idiopathic Pulmonary Fibrosis Drug Details:CG-750 is under development for the treatment of idiopathic pulmonary...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Deudomperidone in Diabetic Gastroparesis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Deudomperidone in Diabetic GastroparesisDrug Details:Deudomperidone (CIN-102) is under development for the treatment of idiopathic and diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – G-001 in Osteoarthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.G-001 in OsteoarthritisDrug Details:G-001 is under development for the treatment of knee osteoarthritis. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Descartes-11 in Refractory Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Descartes-11 in Refractory Multiple Myeloma Drug Details:Descartes-11 is developing for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RG-6287 in Inflammation
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.RG-6287 in Inflammation Drug Details:RG-6287 is under development for the treatment of inflammatory bowel disease, graft...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7303509 in Inflammation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RO-7303509 in Inflammation Drug Details: RO-7303509 is under development for the treatment of inflammation and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RO-7446603 in Diabetic Macular Edema
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RO-7446603 in Diabetic Macular Edema Drug Details: RO-7446603Â is under development for the treatment of diabetic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Triple-Negative Breast Cancer (TNBC) Drug Details: CMP-001 (CYT-003) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Multiple Myeloma (Kahler Disease)Drug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-001 in Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TK-001 in Breast Cancer Drug Details: TK-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Bile Duct Cancer (Cholangiocarcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Bile Duct Cancer (Cholangiocarcinoma)Drug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Anal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Anal CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Pancreatic Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Pancreatic CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Non-Small Cell Lung CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Hypersomnia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Hypersomnia Drug Details: ALKS-2680 is under development for the treatment of narcolepsy...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Ovarian CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Gastric Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Gastric CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Neuroendocrine Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Neuroendocrine CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Solid TumorDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Breast Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Divarasib in Breast CancerDrug Details:Divarasib (GDC-6036 (RG6330)) is under development for the treatment of metastatic or...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.